Selection and use of chemotherapy with hematopoietic growth factors for mobilization of peripheral blood progenitor cells

Current Opinion in Hematology

Volumn 7, Issue 3, 2000, Pages 191-196

  Olavarria, Eduardo ^a   Kanfer, Edward J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANTINEOPLASTIC ACTIVITY; APHERESIS; CANCER; CANCER RADIOTHERAPY; CHEMOTHERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTAPHERESIS; GROWTH SUBSTANCES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS;

EID: 0033995050     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200005000-00011     Document Type: Review

References (49)

1. 1 Shea TC: Introduction: current issues in high-dose chemotherapy and stem cell support. Bone Marrow Transplant 1999, 23(suppl 2):S1-S5.
2. 2 Demirer T, Bensinger WI, Buckner CD: Peripheral blood stem cell mobilization for high-dose chemotherapy. J Hematother 1999, 8(2):103-113. This paper is a good summary of the current knowledge on the use of chemotherapy and cytokines for the mobilization and collection of PBPCs. It also describes the predictive factors for a satisfactory collection and the optimal yield to predict good hematologic recovery after transplantation.
3. 3 Gratwohl A, Passweg J, Baldomero H, Hermans J: Blood and marrow transplantation activity in Europe 1996. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1998, 22:227-240.
4. 4 European Group for Blood and Marrow Transplantation lymphoma registry: XXV EBMT meeting. Bone Marrow Transplant 1999, 24:231-245.
5. 5 Whetton AD, Graham GJ: Trends: Homing and mobilization in the stem cell niche. Cell Biol 1999, 9:233-238.
6. 6 Mohle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L: Regulation of transendothelial migration of hematopoietic progenitor cells. Ann N Y Acad Sci 1999, 872:176-185.
7. 7 Janowska Wieczorek A, Marquez LA, Nabholtz JM, Cabuhat ML, Montano J, Chang H, et al.: Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood 1999, 93:3379-3390.
8. 8 Shpall EJ: The utilization of cytokines in stem cell mobilization strategies. Bone Marrow Transplant 1999, 23(suppl 2):S13-S19.
9. 9 Kroger N, Zeller W, Hassan HT, Kruger W, Gutensohn K, Loliger C, Zander AR: Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 mg/kg) compared to a single dose (1 x 10 microg/kg). Bone Marrow Transplant 1999, 23:125-129.
10. 10 Stiff PJ: Management strategies for the hard to mobilize patient. Bone Marrow Transplant 1999, 23(suppl 2):S29-S33. This paper describes different strategies for mobilization of PBPCs from heavily pretreated patients and patients in whom previous mobilization regimens have failed. It compares the use of G-CSF alone versus G-CSF in combination with SCF in patients with lymphoma in a randomized fashion. For the first time it shows the combination to be superior.
11. 11 Somlo G, Sniecinski I, ter Veer A, Longmate J, Knutson G, Vuk Pavlovic, et al.: Recombinant human thrombopoietin in combination with granulocyte colony stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high dose chemotherapy. Blood 1999, 93:2798-2806.
12. 12 Russell NH, McQuaker G, Stainer C, Byrne JL, Haynes AP: Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplant 1998, 22:935-940. This paper addressed the newly developed disease-oriented mobilization protocols in different subtypes of lymphomas and myelomas. It shows different second-generations regimens to be more effective, especially in the "poor mobilizers" group.
13. 13 Prince HM, Gardyn J, Millward MJ, Rischin D, Francis P, Gates P: Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti tumor activity in patients with metastatic breast cancer. Bone Marrow Transplant 1999, 23:427-435.
14. 14 Weaver CH, Schwartzberg LS, Zhen B, Franco C, Moore M, Smith R Jr, et al.: Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 versus 4 g/m2 of CY. Bone Marrow Transplant 1999, 23:421-425.
15. 15 Benet I, Prosper BF, Marugan I, Lluch A, Arbona C, Castillo J, et al.: Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC). Bone Marrow Transplant 1999, 23:1101-1107.
16. 2, while maintaining its efficacy, can markedly reduce toxicity. It also seems an effective regimen in in whom patients previous chemotherapy-based mobilization protocols have failed.
17. 17 Pecora AL: Impact of stem cell dose on hematopoietic recovery in autologous blood stem cell recipients. Bone Marrow Transplant 1999, 23(suppl 2):7-12.
18. 18 Bojko P, Stellberg W, Kudde C, Scharifi M, Herrmann M, Mayer S, et al.: Kinetic study of CD34+ cells during peripheral blood stem cell collections. J Clin Apheresis 1999, 14:18-25.
19. 19 Yu J, Leisenring W, Bensinger WI, Holmberg LA, Rowley SD: The predicfive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield. Transfusion 1999, 39:442-450. This important study confirms that the peripheral blood CD34 count is the most important factor in predicting the quality and quantity of PBPC collections. It also focuses on the best way of timing the apheresis and its repercussions in a transplant unit.
20. 20 Ford CD, Pace N, Lehman C: Factors affecting the efficiency of collection of CD34 positive peripheral blood cells by a blood cell separator. Transfusion 1998, 38:1046-1050.
21. 21 D'Hondt L, Emmons RV, Andre M, Guillaume T, Feyens AM, Canon JL, et al.: The administration of 10 microg/kg granulocyte colony stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed. Leuk Lymphoma 1999, 34:105-109.
22. 22 Kroger N, Zeller W, Hassan HT, Kruger W, Renges H, Hummel K, et al.: Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann Hematol 1998, 76:257-262.
23. 23 Aurlien E, Holte H, Pharo A, Kvaloy S, Jakobsen E, Smeland EB, et al.: Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998, 21:873-878.
24. 24 Hohaus S, Martin H, Wassmann B, Egerer G, Haus U, Farber L, et al.: Recombinant human granulocyte and granulocyte macrophage colony stimulating factor (G CSF and GM CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Bone Marrow Transplant 1998, 22:625-630.
25. 25 Comenzo RL, Sanchorawala V, Fisher C, Akpek G, Farhat M, Gerda S, et al.: Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999; 104:553-559.
26. 26 Clark RE, Brammer CG: Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998, 22:859-863. The authors validate a previously reported scoring system on an independent group of 99 patients undergoing 103 harvesting episodes. With scoring cut-offs of 21 and 63, they identified groups of patients who would not mobilize PBPC and those who would mobilize optimal numbers with a reduced dose of G-CSF.
27. 27 Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari Corbin A, Tremisi P, el al.: Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998, 103:235-242.
28. 28 Sharp JG, Kessinger A, Clausen SR, Mann SL, O'Kane Murphy: Concurrent partial body radiation prevents cytokine mobilization of blood progenitor cells: an effect mediated by a circulating factor. J Hematother 1998, 7:343-349.
29. 29 Prince HM: Gene transfer: a review of methods and applications. Pathology 1998, 30:335-347.
30. 30 Basser RL: New developments in high dose chemotherapy for breast cancer: recent results. Cancer Res 1998, 152:355-367.
31. 31 Vredenburgh JJ, Silva O, Broadwater G, Berry D, DeSombre K, Tyer C, et al.: The significance of tumor contamination in the bone marrow from high risk primary breast cancer patients treated with high dose chemotherapy and hematopoietic support. Blood Marrow Transplant 1997, 3:91-97.
32. 32 Tarella C, Zallio F, Caracciolo D, Cherasco C, Bondesan P, Gavarotti P, et al.: Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients. Stem Cells 1999, 17:55-61. The authors describe a modified high-dose sequential chemotherapy regimen for in vivo purging of PBPC collections from patients with low-grade lymphoma. To enhance progenitor cell mobilization, a chemotherapy-free lag period was introduced prior to the final mobilizing course.
33. 33 Morton J, Mollee P, Taylor K, Grigg A, Durrant S, Moore D, et al.: Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte colony stimulating factor. Leuk Res 1999, 23:177-183.
34. 34 Carella AM, Lerma E, Corsetti MT, Dejana A, Basta P, Vassallo F, et al.: Autografting With Philadelphia chromosome negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999, 93:1534-1539.
35. 35 Franklin WA, Glaspy J, Pflaumer SM, Jones RB, Hami L, Martinez C, et al.: Incidence of tumor cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony stimulating factor (G CSF) or with G CSF alone. Blood 1999, 94:340-347.
36. 36 Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, et al.: Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant 1998, 22:971-999.
37. 37 Bertolini F, Lanza A, Peccatori F, Zibera C, Gibelli N, Perotti C, et al.: Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte colony stimulating factor (G CSF) or G CSF alone for mobilization. Ann Oncol 1998, 9:913-916.
38. 38 Vescio R, Schiller G, Stewart AK, Ballester O, Noga S, Rugo H, et al.: Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 1999, 93:1858-1868.
39. 39 Tricot G, Gazitt Y, Leemhuis T, Jagannath S, Desikan KR, Siegel D, et al.: Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998, 15:91:4489-4495.
40. 40 Gupta D, Bybee A, Cooke F, Giles C, Davis JG, McDonald C, et al.: CD34+-selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome. Br J Haematol 1999, 104:166-177.
41. 41 Moscow JA, Huang H, Carter C, Hines K, Zujewski J. Cusack G, et al.: Engraftment of MDR1 and NeoR gene transduced hematopoietic cells after breast cancer chemotherapy. Blood 1999, 94:52-61. This study presents an interesting strategy for targeting hemopoietic progenitor cells with a chemotherapy resistance gene before stem cell transplantation in order to produce a survival advantage. The authors show that hematopoietic reconstitution can occur using only PBPCs incubated ex vivo, that the MDR1 gene product may play a role in engraftment, and that chemotherapy may selectively expand MDR1 gene-transduced progenitor cells.
42. 42 Horwitz ME, Malech HL, Anderson SM, Girard LJ, Bodine DM, Orlic D: Granulocyte colony stimulating factor mobilized peripheral blood stem cells enter into G1 of the cell cycle and express higher levels of amphotropic retrovirus receptor mRNA. Exp Hematol 1999, 27:1160-1167.
43. 43 Barranger JA, Rice EO, Swaney WP: Gene transfer approaches to the lysosomal storage disorders. Neurochem Res 1999, 24:601-615.
44. 44 Zentilin L, Tafuro S, Serra C, Falaschi A, Giacca M: Gene therapy of chronic granulomatous disease (CGD) by gene transfer into hematopoietic stem cells. Ist Super Sanita 1998, 34:447-455.
45. 45 Onodera M, Nelson DM, Sakiyama Y, Candotti F, Blaese RM: Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials. Acta Haematol 1999, 101:89-96.
46. 46 Srour EF, Abonour R, Cornetta K, Traycoff CM: Ex vivo expansion of hematopoietic stem and progenitor cells: are we there yet? J Hematother 1999, 8:93-102.
47. 47 Aglietta M, Bertolini F, Carlo Stella C, De Vincentiis A, Lanata L, Lemoli RM, et al.: Ex vivo expansion of hematopoietic cells and their clinical use. Haematologica 1998, 83:824-848.
48. 48 McNiece I, Jones R, Cagnoni P, Bearman S, Nieto Y, Shpall EJ: Ex vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. Hematol Cell Ther 1999, 41:82-86.
49. 49 Goodell MA: CD34+ or CD34-: does it really matter? Blood 1999, 94:2545-2547.